The correlation between CXCL5 expression and macrophage infiltration in GC suggests that targeting the CXCL5/PI3K/AKT/mTOR axis could enhance the efficacy of 5‐FU therapy by reducing M2 macrophage polarization and improving patient outcomes. The gene discussed is PIK3CD; the disease is gastric cancer.